FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC

Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes:

The U.S. Food and Drug Administration (FDA) has approved another new drug for people with metastatic non-small cell lung cancer (NSCLC) tumors that have high levels of a protein called PD-L1.

Go to full article published by OncLive.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.